Investigational drug · Phase 2
HBI-002
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson Disease, Anemia, Sickle Cell.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "HBI-002"
First trial start
2025
Feb 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HBI-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
- Anemia, Sickle Cell
Approved drugs for the same conditions: Sickle cell disease · Anemia · Parkinson's disease · Hematology and blood cancers · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "HBI-002" as an intervention, largest first.
Hillhurst Biopharmaceuticals, Inc.Industry
NCT07005180 · 36 participants (planned) · Start Jun 30, 2026 · Primary completion Dec 31, 2026
Drug: HBI-002; Vehicle (placebo) · For: Parkinson Disease
Sites: Fountain Valley, California; Gainesville, Florida; Boston, Massachusetts · 8 sites in all
Hillhurst Biopharmaceuticals, Inc.Industry
NCT03926819 · 20 participants · Start Jul 25, 2022 · Primary completion Apr 26, 2023
Drug: HBI-002 · For: Anemia, Sickle Cell
Sites: San Diego, California
Hillhurst Biopharmaceuticals, Inc.Industry
NCT06144749 · 13 participants · Start Feb 15, 2025 · Primary completion Jun 30, 2026
Drug: HBI-002 · For: Anemia, Sickle Cell
Sites: Panama City, Panama · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity.
Alves de Souza RW, Voltarelli V, Gallo D, et al. · J Am Heart Assoc 2024
- Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia.
Belcher JD, Gomperts E, Nguyen J, et al. · PLoS One 2018
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
- AP-472Phase 21 trial
Appello Pharmaceuticals, Inc. · Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.